These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22250808)

  • 1. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A.
    Nemes L; Pollmann H; Becker T
    Haemophilia; 2012 Jul; 18(4):496-502. PubMed ID: 22250808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Personification of the standard treatment of patients with hemophilia A (results of a multicenter Russian open-labeled prospective study evaluating the use of haemoctin)].
    Zozulia NI; Pliushch OP
    Ter Arkh; 2010; 82(4):56-61. PubMed ID: 20481218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.
    Matysiak M; Bobrowska H; Balwierz W; Chybicka A; Kowalczyk JR; Shaikh-Zaidi R; Gillanders K; Dash CH
    Haemophilia; 2011 Sep; 17(5):737-42. PubMed ID: 21699629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.
    Pollmann H; Externest D; Ganser A; Eifrig B; Kreuz W; Lenk H; Pabinger I; Schramm W; Schwarz TF; Zimmermann R; Zavazava N; Oldenburg J; Klamroth R
    Haemophilia; 2007 Mar; 13(2):131-43. PubMed ID: 17286765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
    Klamroth R; Holzhauer S; Zimmermann R; Heller C; Kurnik K;
    Thromb Res; 2014 Nov; 134 Suppl 1():S16-21. PubMed ID: 24418255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ
    Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.